Cymbalta (Duloxetine)
Cymbalta is an SNRI used to treat depression, anxiety, fibromyalgia, & diabetic neuropathy, offering benefits for both mood & pain management through central sensitization pathways.
Evidence last reviewed: 05 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
Cymbalta has strong evidence supporting its effectiveness in preventing major depressive disorder relapse and managing fibromyalgia and chemotherapy-induced neuropathy symptoms. However, withdrawal symptoms upon discontinuation are a notable concern, indicating the need for careful management.
Fibromyalgia symptom improvementAdults with fibromyalgia · Systematic review and meta-analysisHigh
Duloxetine was more effective than placebo in managing fibromyalgia symptoms.
Major depressive disorder relapse preventionAdults with major depressive disorder · Systematic review and network meta-analysisHigh
Duloxetine was effective in preventing relapse in the maintenance phase of major depressive disorder.
Chemotherapy-induced peripheral neuropathy symptom managementPatients with chemotherapy-induced peripheral neuropathy · Systematic review and meta-analysisHigh
Duloxetine was effective in improving symptoms of chemotherapy-induced peripheral neuropathy.
Withdrawal symptoms upon discontinuationPatients discontinuing SNRI treatment · Systematic reviewModerate
Withdrawal symptoms were common after discontinuation of SNRIs, including duloxetine.